Science Corporation closed a $230 million Series C round led by Lightspeed, Khosla Ventures, and Y Combinator, bringing total funding to $490 million. The startup's flagship product PRIMA is a 2-millimeter retinal implant with 378 pixel-electrodes that works with specialized infrared glasses to restore functional vision in patients with late-stage macular degeneration — the leading cause of blindness.
In clinical trials across Europe and the US involving 47 patients, 80% demonstrated meaningful improvement in visual acuity and were able to read letters, numbers, and words. Science Corp has submitted a CE mark application and expects EU approval in mid-2026, with an FDA application also in progress.
The company, founded by former Neuralink co-founder Max Hodak, operates its own fabrication facility in North Carolina and plans to use the new capital to scale manufacturing. Beyond PRIMA, Science Corp is developing Biohybrid, a higher-bandwidth brain-computer interface using electrodes and microLEDs.
